All Outputs (5)

Saliva for COVID-19 testing: Simple but useless or an undervalued resource? (2021)
Journal Article
Pijuan-Galito, S., Tarantini, F. S., Tomlin, H., Jenkins, H., Thompson, J. L., Scales, D., …Denning, C. (2021). Saliva for COVID-19 testing: Simple but useless or an undervalued resource?. Frontiers in Virology, 1, Article 778790. https://doi.org/10.3389/fviro.2021.778790

During the COVID-19 pandemic, countries with robust population-based asymptomatic testing were generally successful in controlling virus spread, hence reducing hospitalizations and deaths. This effectiveness inspired widespread asymptomatic surveilla... Read More about Saliva for COVID-19 testing: Simple but useless or an undervalued resource?.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection (2021)
Journal Article
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., …Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 13(609), Article eabj0847. https://doi.org/10.1126/scitranslmed.abj0847

Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 (2017)
Journal Article
Mesalam, A. A., Desombere, I., Farhoudi, A., Van Houtte, F., Verhoye, L., Ball, J., …Meuleman, P. (2018). Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. Virology, 514, https://doi.org/10.1016/j.virol.2017.10.019

Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly against envelope protein 2 (E2), while the antigenic epitopes of envelope protein 1 (E1) are not fully identified. Here we describe the detailed chara... Read More about Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo (2017)
Journal Article
Desombere, I., Mesalam, A. A., Urbanowicz, R. A., Van Houtte, F., Verhoye, L., Keck, Z., …Meuleman, P. (2017). A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Research, 148, https://doi.org/10.1016/j.antiviral.2017.10.015

Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immedia... Read More about A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Human Adaptation of Ebola Virus during the West African Outbreak (2016)
Journal Article
Urbanowicz, R. A., McClure, C. P., Sakuntabhai, A., Sall, A. A., Kobinger, G., Müller, M. A., …Ball, J. K. (2016). Human Adaptation of Ebola Virus during the West African Outbreak. Cell, 167(4), 1079-1087.e5. https://doi.org/10.1016/j.cell.2016.10.013

The 2013–2016 outbreak of Ebola virus (EBOV) in West Africa was the largest recorded. It began following the cross-species transmission of EBOV from an animal reservoir, most likely bats, into humans, with phylogenetic analysis revealing the cocircul... Read More about Human Adaptation of Ebola Virus during the West African Outbreak.